Pharmaxis Ltd. (Nasdaq: PXSL) has recently lodged the registration documents for marketing approval of its asthma management product (Aridol) with the Swiss regulatory agency for therapeutic products, Swissmedic.
Trimedal AG, a specialist respiratory and allergy pharmaceutical company based in Zurich will distribute Aridol.
Dr Alan Robertson, Pharmaxis Chief Executive Officer said; "Several important clinical trials for Aridol have taken place in Switzerland and, as a result, respiratory physicians are enthusiastic to have Aridol available.
Swiss registration will augment our regulatory coverage in Europe, and allow us to move forward uniformly with the marketing and sales activities for Aridol."
Switzerland as we all know is not part of the European Union (EU), therefore new medicines are subject to separate regulatory review.
Aridol is currently under review by the Swedish Medical Products Agency as part of the mutual recognition procedure that will allow Pharmaxis to sell the product throughout the European Union.
Source: Pharmaxis Ltd. Press Release (a pdf file)
.jpg)
Comment Preview